Drug intelligence / Profile preview

Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells

Development stage: Unknown
Lead developer: Zhongshan Hospital, Fudan University
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
Administration: Intravenous

Overview

Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells is an investigational autologous CAR-T cell therapy developed by Shanghai Zhongshan Hospital for the treatment of relapsed or refractory hepatocellular carcinoma (HCC). This biologic therapy involves the ex vivo genetic engineering of a patient's T cells to express a chimeric antigen receptor (CAR) that specifically targets the Interleukin-1 receptor accessory protein (IL1RAP). IL1RAP is a cell surface protein that is significantly overexpressed in HCC compared to normal liver tissue, making it a viable target for directed immunotherapy. The therapy is currently being evaluated in a Phase 1 dose-escalation clinical trial (NCT06757881) to assess its safety, tolerability, and preliminary anti-tumor activity in adult patients.

Other names: IL1RAP-targeting Chimeric Antigen Receptor T CellsIL-1RAP-targeting Chimeric Antigen Receptor T CellsIL 1RAP-targeting Chimeric Antigen Receptor T Cellsanti-IL1RAP CAR-T cellsanti-IL-1RAP CAR-T cellsanti-IL 1RAP CAR-T cellsGene modified anti-IL1RAP Chimeric Antigen Receptor T Cells-Shanghai Zhongshan Hospital-hepatocellular carcinoma

Targets

IL1RAP (Interleukin 1 receptor accessory protein)

Beyond the preview

Go deeper on Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells.

Explore the full profile